The FDA accepted Pfizer's biologics license application for its pentavalent meningococcal vaccine candidate intended for people between the ages of 10 and 25.
The candidate is a combination of Pfizer's two licensed meningococcal vaccines, according to a Dec. 28 news release from Pfizer. If the product is approved, the meningococcal vaccine would be the first to change the two- to four-dose series into one jab.
Pfizer said it expects a final decision by October 2023.